To determine whether the glycan effect on cognitive decline was independent of CSF amyloid/tau biomarker status, we also adjusted the linear models with cognitive performance as the outcome variable by adding baseline A/T status as predictor variables. This evidence concerns the gene MAPT and Mental deterioration.